Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic Acid vs Risedronate in Paget's Disease of Bone
NCT00051636Phase 3Completed
- Sponsor
- Novartis
- Start
- Jan 2001
- Primary completion
- Mar 2004
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial of zoledronic acid in Paget's disease of bone (2 arms), sponsored by Novartis. Primary endpoint: Number of Patients Who Achieve Therapeutic Response at 6 Months. Started Jan 2001; status: completed.
02
Drugs
zoledronic acid
03
Conditions
Paget's disease of bone
Beyond the preview
Go deeper on NCT00051636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00051636.